Cancer drug imatinib tested on rare eye melanoma

NCT ID NCT00421317

Terminated Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Mar 20, 2026 · Last updated May 13, 2026 · Updated 9 times

Summary

This study tested the drug imatinib in 13 adults with ocular melanoma that had spread to other parts of the body. The goal was to see if the drug could stop or slow tumor growth. The trial was stopped early, and results were limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Centre Francois Baclesse

Caen, 14076, France
Centre Georges-Francois Leclerc

Dijon, 21079, France
Centre Gustave Roussy

Villejuif, 94805, France
Centre Hospitalier Regional Universitaire

Lille, 59035, France
Centre Jean Perrin

Clermont-Ferrand, 63011, France
Centre Leon Berard

Lyon, 69373, France
Centre Oscar Lambret

Lille, 59020, France
Centre Paul Strauss

Strasbourg, 67065, France
Centre Val d'Aurelle Paul Lamarque

Montpellier, 34298, France
Hopital Universitaire de Hautepierre

Strasbourg, 67098, France
Institut Claudius Regaud

Toulouse, 31052, France
Institut Curie

Paris, 75248, France

Conditions

Explore the condition pages connected to this study.

MELANOMA